Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Chronic Pancreatitis II: Collaborative Care

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cancer history and second cancer risk in polycythemia vera and essential thrombocythemia.

Blood cancer journal·2026

Same author

Distinct Longitudinal Patterns of Basal and Squamous Cell Carcinoma in Polycythemia Vera and Essential Thrombocythemia.

American journal of hematology·2026

Same author

Venetoclax and gilteritinib combination for <i>FLT3</i>-mutated relapsed/refractory acute myeloid leukemia: a real-world single-center experience.

Haematologica·2026

Same author

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

Blood advances·2026

Same author

APL-like subset within <i>NPM1</i>-mutated AML: A distinct immunophenotype correlating with early vascular complications.

HemaSphere·2026

Same author

Autoimmune and Inflammatory Diseases in Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcomes and Comorbidities.

American journal of hematology·2026

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Chronic myeloproliferative neoplasms: a collaborative approach.

Lisa Pieri¹, Paola Guglielmelli, Alessandro M Vannucchi

¹Unità Funzionale di Ematologia, Dipartimento di Area Critica, Università degli Studi, Istituto Toscano Tumori, Firenze.

Mediterranean Journal of Hematology and Infectious Diseases

|March 19, 2011

Summary

Chronic myeloproliferative neoplasms (MPNs) present diagnostic and management challenges. Current therapies focus on reducing thrombosis risk without increasing transformation risks, especially for Polycythemia Vera and Essential Thrombocythemia.

More Related Videos

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

Related Experiment Videos

Last Updated: Jun 3, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

Area of Science:

Hematology
Oncology

Background:

Chronic myeloproliferative neoplasms (MPNs) encompass diverse conditions with complex diagnostic and management needs.
Polycythemia Vera and Essential Thrombocythemia are the most prevalent MPNs, associated with significant morbidity and mortality due to thrombosis and transformation to myelofibrosis or acute leukemia.
While survival is minimally impacted in these common MPNs, primary myelofibrosis carries a substantially reduced survival rate and disabling symptoms.

Purpose of the Study:

To review key clinical issues in the management of MPNs.
To emphasize the need for an integrated, patient-centered approach to MPN care.
To discuss therapeutic strategies balancing thrombosis risk reduction and transformation risk mitigation.

Main Methods:

Literature review of chronic myeloproliferative neoplasms.
Analysis of diagnostic and therapeutic challenges in MPNs.
Discussion of risk-oriented patient stratification for treatment.

Main Results:

MPNs, including Polycythemia Vera and Essential Thrombocythemia, pose significant challenges in diagnosis and management.
Thrombosis is a major cause of morbidity and mortality, while transformation to acute leukemia or myelofibrosis is a concern.
Therapeutic strategies aim to reduce thrombosis without exacerbating transformation risks, particularly with cytotoxic drugs.

Conclusions:

Optimal management of MPNs requires an integrated, patient-oriented strategy.
Risk stratification is crucial for selecting appropriate therapies, especially in primary myelofibrosis where survival is significantly reduced.
Balancing treatment benefits against potential risks is essential for improving patient outcomes in MPNs.